CAMBRIDGE, Mass.– AIRNA, a biotechnology company pioneering RNA editing therapeutics for rare and common diseases, today announced the appointments of Allison Dorval as Chief Financial Officer (CFO) and Niru Subramanian as Chief Operating Officer (COO).
“AIRNA is at an exciting inflection point as we prepare for AIR-001 to enter the clinic as a potential best-in-class treatment for patients with alpha-1 antitrypsin deficiency,” said Kris Elverum, President and Chief Executive Officer of AIRNA. “Both Allison and Niru bring extensive company-building expertise and their appointments strengthen our ability to accelerate development, progress our pipeline, and fulfill the promise of RNA editing.”
Dorval brings more than 25 years of experience in financial leadership, primarily with early-stage biotechnology companies. She most recently served as CFO of Verve Therapeutics, where she oversaw financial strategy and execution and played a pivotal role in its acquisition by Eli Lilly. She previously held CFO roles at Voyager Therapeutics and senior finance leadership positions at other biopharmaceutical firms.
“AIRNA has unique potential to grow a strong and diversified business by developing RNA editing therapeutics, beginning with its potentially transformative medicine for alpha-1 antitrypsin deficiency,” said Dorval. “I am excited to work together with this experienced team to deliver safe and convenient genetic medicines across both rare and common conditions.”
Subramanian also brings more than 25 years of experience in business development, strategy, and portfolio and program management across the biotech and pharmaceutical sectors. She most recently served as COO of Orbital Therapeutics and previously was COO of Rheos Medicines. At Agios Pharmaceuticals, she led corporate development and planning, driving the $2 billion sale of the company’s oncology portfolio to Servier. She also held senior leadership roles at Novartis.
“Patients with AATD desperately need new therapeutic options, and I’m thrilled to join AIRNA as the company is preparing to bring AIR-001 into clinical trials,” said Subramanian. “AIRNA has developed a distinctive RNA editing platform that harnesses unique human genetics insights to create a robust pipeline of medicines across multiple therapeutic areas.”
